Meridian Bioscience — Q2 FY2020 Earnings Presentation
20 slides from Meridian Bioscience's earnings presentation, May 8, 2020
Slide 1: FY2020 Q2 Results
FY2020 Q2 Results May 8, 2020 Exhibit 99.2
Slide 2: Forward-looking statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within the meaning of Section 27A
Slide 3: Non-GAAP Financial Measures
Certain financial measures presented in this presentation, such as operating expenses, operating income, net earnings and diluted earnings per share, excluding as applicable the effects of acquisition-related costs, a change in fair value of contingent consideration obligation, restructuring costs a
Slide 4: Q2 FY2020 Business Highlights
Life Science rapidly responds to COVID-19 & record revenue YoY quarterly revenue growth for Diagnostics segment Curian® analyzer and HpSA ® assay receive FDA clearance Acquisition of Exalenz Bioscience Ltd. and BreathID ® platform Q2 FY2020 Business Highlights Diagnostics Life Science
Slide 5: FY2020 Second Quarter Earnings Summary
FY2020 Second Quarter Earnings Summary ($000’s except Per Share Amounts) Adjusted (Non-GAAP) FY2020 FY2019 Change Revenue $57,296 $50,248 +14% Gross Margin % 60.1% 58.4% +1.7 pts Operating expenses(1) Ratio $22,380 39.1% $18,115 36.1% +24% +3.0 pts Operating income Margin % $12,074 21.1% $11,223 22.
Slide 6: FY2020 Second Quarter Operating Segment Highlights
FY2020 Second Quarter Operating Segment Highlights ($000’s) Diagnostics (Adjusted Non-GAAP) FY2020 FY2019 Change Revenue $34,942 $33,500 +4% Operating income Margin % $3,337 9.6% $7,436 22.2% -55% -12.6 pts Diagnostics revenue by: Technology: Molecular assays $7,238 $7,084 +2% Immunoassays & blood c
Slide 7: FY2020 Fiscal Year Guidance
FY2020 Fiscal Year Guidance Meridian Bioscience Consolidated net revenues: Flat to Down 3% Adjusted operating margin: 9% to 10% Tax rate: 23.5% to 24.5% Adjusted earnings per share: $0.28 to $0.34 Research and development spend: $27 to $28 Million Diagnostics Net revenues: Down 3% to 5% Adjusted ope
Slide 8: COVID-19 Response
COVID-19 Response ~~
Slide 9: COVID-19 Products & Pipeline
COVID-19 Products & Pipeline DIAGNOSTICS LIFE SCIENCE Reagent Master Mixes Recombinant Antigens RI Panel w/ SARS-CoV-2 (In Development) Rapid Immunoassay For Tests to check for SARS-CoV-2 Antibodies For Tests to check for SARS-CoV-2 Virus Spike proteins Nucleocapsid Molecular Immunological Molecular
Slide 10: Exalenz Bioscience Ltd. Acquisition
Exalenz Bioscience Ltd. Acquisition
Slide 11: Exalenz Strategic Fit and Rationale
Exalenz Strategic Fit and Rationale Adds multi-configuration BreathID® diagnostics platform Flexible configurations span the continuum from large reference labs to point-of-care H. pylori urea breath test compliments stool antigen tests Strengthens opportunity to convert of H. pylori serology testin
Slide 12: Exalenz BreathID System
High volume Independent Labs LAB Large Hospitals Automated benchtop system for press and walk away batch testing Samples collected in physician office using breath bags sent to centralized location Test up to 10 patients at a time 100% sensitivity / 97.9% specificity Low volume Physician Office Labs
Slide 13: Specimen Collection Workflow for BreathID
Breath bags are placed on analyzer and results are read within 2 minutes POST-INGESTION breath sample collected by patient blowing into GRAY breath bag Patient drinks 13C Urea labeled solution and waits 20 minutes BASELINE breath sample collected by patient blowing into BLUE breath bag Specimen Coll
Slide 14: BreathID Assay Workflow
Scan bag barcode Batch set up Press start Step 1 Step 2 Step 3 Start Results In 2 minutes BreathID® Assay Workflow
Slide 15: Historical Financial Overview
Historical Financial Overview Source: Exalenz Bioscience Ltd. 2019 consolidated financial statements prepared in accordance with IFRS; accounting policies under IFRS may differ from Meridian’s accounting under U.S. GAAP.
Slide 16: Curian Analyzer
Curian® Analyzer ~~
Slide 17: The Curian Advantage
Fluorescent analyzer Improved performance with no subjectivity Intuitive user interface Intuitive, fast, and easy-to-use improves productivity Simple sample prep Clean, comfortable handling of samples Easy, standardized workflow Implement & train only once The Curian® Advantage
Slide 18: Curian Present and Future
C. difficile GDH/Toxin Campy EHEC Future Assay Roadmap Current Menu HpSA® Launched May 1st, 2020 Curian® Present and Future
Slide 19: Curian Assay Workflow
Discharge sample & vortex Add sample to device card Place card into analyzer and start Step 1 Step 2 Step 3 Curian® Assay Workflow Standardized Simplified Workflow Curian Video
Slide 20: Contact
Contact: mbi@meridianbioscience.com
Meridian Bioscience — Q2 FY2020 Earnings Presentation on 6ix